Q & A: The Alzheimer's disease neuroimaging initiative
نویسنده
چکیده
What is the Alzheimer’s Disease Neuroimaging Initiative and who funds it? The Alzheimer’s Disease Neuroimaging Initiative (ADNI) is a large, highly collaborative longitudinal cohort study aiming to elucidate biomarker trajectories in Alzheimer’s disease (AD). ADNI was initially funded in 2004, based on the urgent need to understand potential biomarkers better in order to facilitate drug development, and the large cost and effort required to conduct appropriate studies. About two thirds of its budget is provided by the US National Institute on Aging (NIA), and about one third comes from pharmaceutical companies; private foundations have also contributed.
منابع مشابه
Detection of Alzheimer\\\\\\\'s Disease using Multitracer Positron Emission Tomography Imaging
Alzheimer's disease is characterized by impaired glucose metabolism and demonstration of amyloid plaques. Individual positron emission tomography tracers may reveal specific signs of pathology that is not readily apparent on inspection of another one. Combination of multitracer positron emission tomography imaging yields promising results. In this paper, 57 Alzheimer's disease neuroimaging ini...
متن کاملBRAIN A JOURNAL OF NEUROLOGY Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer’s disease
Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer’s disease Clifford R. Jack Jr, Heather J. Wiste, Prashanthi Vemuri, Stephen D. Weigand, Matthew L. Senjem, Guang Zeng, Matt A. Bernstein, Jeffrey L. Gunter, Vernon S. Pankratz, Paul S. Aisen, Michael W. Weiner, Ronald C. Petersen, Leslie M. Shaw, John Q...
متن کاملThe Alzheimer's disease neuroimaging initiative.
With increasing life expectancy in developed countries, the incidence of Alzheimer's disease (AD) and its socioeconomic impact are growing. Increasing knowledge of the mechanisms of AD facilitates the development of treatment strategies aimed at slowing down or preventing neuronal death. AD treatment trials using clinical outcome measures require long observation times and large patient samples...
متن کاملNeurology the Alzheimer ’ s Disease Neuroimaging Initiative
2009;73;1193-1199 Neurology the Alzheimer’s Disease Neuroimaging Initiative Reiman, N. L. Foster, R. C. Petersen, M. W. Weiner, J. C. Price, C. A. Mathis and For W. J. Jagust, S. M. Landau, L. M. Shaw, J. Q. Trojanowski, R. A. Koeppe, E. M. Relationships between biomarkers in aging and dementia This information is current as of October 15, 2009 http://www.neurology.org/cgi/content/full/73/15/11...
متن کاملCSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts
INTRODUCTION We studied whether fully automated Elecsys cerebrospinal fluid (CSF) immunoassay results were concordant with positron emission tomography (PET) and predicted clinical progression, even with cutoffs established in an independent cohort. METHODS Cutoffs for Elecsys amyloid-β1-42 (Aβ), total tau/Aβ(1-42), and phosphorylated tau/Aβ(1-42) were defined against [18F]flutemetamol PET in...
متن کامل